Ferriprox Approved in Brazil to Treat Iron Overload in SCD Patients

Ferriprox Approved in Brazil to Treat Iron Overload in SCD Patients

306275

Ferriprox Approved in Brazil to Treat Iron Overload in SCD Patients

Regulators in Brazil have approved Ferriprox (deferiprone), Chiesi Global Rare Diseases’ iron-binding oral treatment, for blood transfusion-induced iron overload in people with sickle cell disease (SCD) or other anemias. Ferriprox’s use was also approved in combination with other iron-binding, or iron-chelating, treatments for people with thalassemia major, a severe inherited blood disorder, when single therapy is ineffective, or when the consequences of iron overload are seen as life threatening. The therapy was previously available in the…

You must be logged in to read/download the full post.